SR ONE CAPITAL MANAGEMENT, LP

SR One Capital Management, LP is a specialized life sciences investment firm headquartered in Conshohocken, Pennsylvania, with a distinctive focus on the healthcare and biotechnology sectors. The firm traces its heritage to SR One, the venture capital arm of GlaxoSmithKline (GSK), one of the world's largest pharmaceutical companies. This pharmaceutical industry lineage provides SR One Capital Management with deep domain expertise and scientific networks uncommon among generalist investment managers. The firm files 13F reports with the SEC under CIK #0001910264, providing quarterly transparency into its publicly traded equity positions. The firm's leadership brings extensive experience in life sciences investing and pharmaceutical industry operations. Simeon George, serving as Managing Partner and Chief Investment Officer, previously led SR One's venture capital activities and brings deep understanding of drug development, clinical trial dynamics, and healthcare company valuation. Barbara Dalton, as Managing Partner, contributes significant experience in life sciences venture capital and investment management. This leadership combination positions the firm with scientific sophistication essential for navigating complex biotechnology investments. Conshohocken's location in the greater Philadelphia area places the firm within a major life sciences hub, with proximity to pharmaceutical headquarters, academic medical centers, and biotechnology companies concentrated in the Pennsylvania-New Jersey corridor. This regional ecosystem provides access to scientific talent, industry relationships, and emerging opportunities within the healthcare innovation landscape. The platform enables examination of the firm's 13F Portfolio Composition and tracking of its healthcare-focused investment philosophy across market cycles.

SR One Capital Management employs a highly specialized investment strategy concentrated in the life sciences sector, leveraging deep domain expertise to identify compelling opportunities across biotechnology, pharmaceuticals, medical devices, diagnostics, and healthcare services. The firm's pharmaceutical heritage provides differentiated insight into drug development pipelines, clinical trial interpretation, regulatory pathways, and commercial launch dynamics that generalist investors struggle to replicate. The investment process integrates fundamental scientific analysis with financial evaluation, assessing therapeutic mechanisms, clinical data quality, competitive positioning, and commercial potential alongside traditional valuation metrics. This multi-disciplinary approach enables identification of mispriced securities where market consensus fails to accurately assess pipeline probabilities, regulatory outcomes, or commercial trajectories. The firm's extensive network within pharmaceutical and academic research communities provides proprietary insights supporting investment thesis development. Portfolio construction reflects concentrated exposure to the healthcare and life sciences universe, with positions spanning large-cap pharmaceutical companies, mid-cap specialty pharma and biotech, and smaller emerging biotechnology firms pursuing innovative therapeutics. Sector Allocation History analysis reveals positioning across healthcare subsectors, with observable concentrations shifting based on scientific developments, regulatory catalysts, and relative valuations. Top 10 Holdings Concentration examination provides insight into conviction weighting across the life sciences spectrum. The firm's heritage in venture capital investing informs a perspective spanning public and private markets, understanding how private company valuations, financing dynamics, and IPO markets affect publicly traded life sciences securities. Users can analyze the firm's Historical Track Record through simulated replication of disclosed positions, normalized to a user-defined notional, to assess how this specialized healthcare approach has performed across different market environments.

SR One Capital Management, LP represents a specialized life sciences investment firm with distinctive pharmaceutical industry heritage positioning it uniquely within the healthcare investment landscape. The Conshohocken-based firm, led by Simeon George and Barbara Dalton with deep backgrounds in life sciences venture capital and pharmaceutical operations, applies differentiated scientific expertise to identify opportunities across biotechnology, pharmaceuticals, and healthcare innovation. Key analytical characteristics observable from 13F filings include concentrated healthcare sector exposure, positioning across the life sciences spectrum from large-cap pharma to emerging biotech, and portfolio construction reflecting deep domain expertise rather than generalist diversification. The firm's pharmaceutical heritage provides scientific networks and analytical capabilities uncommon among financial investors. The platform enables users to simulate historical capital trajectories based on disclosed holdings, examine risk-adjusted outcomes including Sharpe Ratio calculations, and analyze subsector positioning within the healthcare universe over time. Such analysis provides context for evaluating how specialized life sciences expertise translates to investment outcomes across different biotechnology market regimes. The firm's evolution from GlaxoSmithKline's venture capital arm to an independent investment manager reflects broader industry trends toward specialized, domain-expert investment approaches in complex sectors. This pharmaceutical industry pedigree distinguishes SR One Capital from financial-first investors, potentially enabling more accurate assessment of clinical probabilities and pipeline valuations. Given the firm's CIK registration in 2022, the 13F filing history captures a challenging period for biotechnology investing including the sector's significant correction from 2021 peaks. Continued observation will enable more comprehensive assessment of how the firm's specialized approach navigates varying healthcare market conditions. A diagnostic question for further exploration: How does SR One Capital Management's portfolio sensitivity to biotech sector indices (such as the XBI or IBB) compare to broader healthcare exposure, and do observable subsector allocation shifts anticipate or follow major clinical and regulatory catalysts within the life sciences space?

The risk characteristics of SR One Capital Management's disclosed portfolio reflect its concentrated sector exposure to healthcare and life sciences—among the most volatile segments of the equity market. Biotechnology securities exhibit elevated Volatility Profile metrics driven by binary clinical trial outcomes, regulatory decisions, and competitive developments that can trigger dramatic price movements in either direction. This inherent sector volatility demands sophisticated risk management and conviction in underlying research processes. Healthcare sector concentration creates distinct risk dynamics including clinical trial failure risk, regulatory rejection risk, competitive displacement risk, and reimbursement/pricing risk that operate somewhat independently of broader market factors. A single Phase III clinical trial failure can eliminate substantial market capitalization overnight, while positive data readouts can generate equally dramatic appreciation. Max Drawdown Depth analysis across historical periods reveals how the portfolio has navigated these sector-specific stress events. The biotech sector experienced severe drawdowns during 2021-2022 as speculative excess unwound and rising interest rates compressed valuations for cash-burning development-stage companies. This period tested healthcare-focused strategies intensively, distinguishing managers with rigorous scientific analysis from those pursuing momentum in speculative names. The firm's pharmaceutical industry heritage and fundamental research orientation may provide differentiation during such corrective periods. Downside Capture Ratio analysis derived from 13F replication quantifies portfolio behavior during declining markets, though healthcare sector exposure can create performance divergence from broad indices during periods of sector-specific stress or outperformance. The firm's relatively recent 13F filing history, beginning in 2022, limits full-cycle assessment but captures a challenging period for life sciences investing.